New Groundbreaking DNA Study of 500,000 People Launched to Find New Links Between Genetics and Diseases

Study Represents Largest DNA Mapping Effort Undertaken in U.S. From a Single Population


  • newswise-fullscreen New Groundbreaking DNA Study of 500,000 People Launched to Find New Links Between Genetics and Diseases

    Credit: Intermountain Healthcare

    The HerediGene: Population Study, represents the largest and most comprehensive DNA mapping effort to date in the United States from a single population.

Newswise — REYKJAVIK, ICELAND, and SALT LAKE CITY – Intermountain Healthcare and deCODE genetics have announced a major global collaboration and study focused on discovering new connections between genetics and human disease that will involve the collection of half a million DNA samples.

The initiative, called the HerediGene: Population Study, represents the largest and most comprehensive DNA mapping effort to date in the United States from a single population. For the study, which is voluntary and free to participants, Intermountain teams will work with deCODE to analyze the genomes of 500,000 people from Intermountain’s patient population, primarily in Utah and Idaho.

Intermountain Healthcare is a Utah-based not-for-profit integrated healthcare delivery network, and deCODE Genetics is a wholly owned subsidiary of Amgen based in Reykjavik, Iceland. The collaborative effort combines Intermountain’s internationally-recognized expertise in precision medicine and clinical care with deCODE’s world-class expertise in human population genetics.

“While the 500,000 samples will be collected primarily from patients in Utah, the research is expected to have a global impact as medications, treatments, and healthcare innovations that can benefit patients universally are developed from the findings,” said Lincoln Nadauld, MD, PhD, Intermountain’s chief of precision health. “The collaboration is noteworthy and unique in its size, scope, and immediate application to patient care.”

Participants in the study will consent to the testing and have the option to receive their genetic results report, if a clinically significant gene mutation is identified. The data will be de-identified to ensure anonymity before it is utilized in research to help medical professionals better understand the human genome, which will enhance their ability to predict and prevent diseases such as breast cancer, colon cancer, and heart disease.

“This unique collaboration is expected to uncover new insights into some of society’s most debilitating diseases,” noted Kári Stefánsson, MD, Dr. Med., founder and chief executive officer of deCODE genetics. “Our partnership with Intermountain Healthcare is important as we continue to identify and validate human disease targets. These potential discoveries will allow deCODE and Amgen to rapidly develop new medicines that reach the right disease targets.”

Intermountain will leverage its renowned precision genomics efforts to improve patient outcomes and transform medicine. Intermountain’s precision medicine team analyzes individual differences in genetics, environments, and lifestyles and helps medical professionals specifically target the illnesses of each patient and identify the treatments that will best help them.

“Better health and being able to cure common diseases is the promise of precision medicine, but it’s not happening fast enough,” said Marc Harrison, MD, president and chief executive officer at Intermountain Healthcare. “For too long, the genetic code to better health has been locked. This collaboration with deCODE unlocks that insight so we can rapidly advance well-being – not only for ourselves and our families, but for generations to come.”

Insights from the collaboration may power fundamental changes to better understand the human genome, improve health, and prevent common diseases.

For more information on the study, please go to Intermountainhealthcare.org/heredigene.

###

About deCODE geneticsBased in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases. Understanding the genetics of disease can create new means of diagnosing, treating and preventing disease. deCODE is a wholly-owned subsidiary of Amgen.

About Intermountain Intermountain Healthcare is a Utah-based not-for-profit system of 24 hospitals, 160 clinics, a Medical Group with some 2,300 employed physicians and advanced care practitioners, a health insurance company called SelectHealth, and other health services. Intermountain is widely recognized as a leader in transforming healthcare through evidence-based best practices, high quality, and sustainable costs. For more information about Intermountain, visit intermountainhealthcare.org.

Amgen Forward-Looking StatementsThis news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed, and actual results may differ materially from those Amgen project. Amgen’s results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen’s products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen’s research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen’s business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen’s business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for Amgen’s products are supplied by sole third-party suppliers. Certain of Amgen’s distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen’s products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen’s efforts to acquire other companies or products and to integrate the operations of companies Amgen has acquired may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of Amgen’s systems and Amgen’s data. Amgen’s stock price may be volatile and may be affected by a number of events. Amgen’s business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all.

The scientific information discussed in this news release related to Amgen’s product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Further, the scientific information discussed in this news release relating to new indications for Amgen’s products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.

 

  • share-facebook-New Groundbreaking DNA Study of 500,000 People Launched to Find New Links Between Genetics and Diseases
  • share-twitter-New Groundbreaking DNA Study of 500,000 People Launched to Find New Links Between Genetics and Diseases

Comment/Share

step 2
Chat now!